Notice: Prescription Drug List (PDL): Multiple Additions (2020-02-13)

The purpose of this Notice of Amendment is to notify about the additions of gemtuzumab ozogamacin, gilteritinib, icosapent ethyl, tafamidis, trifarotine and upadacitinib to the Prescription Drug List (PDL) for human and/or veterinary use.

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 21:33 (UTC)
Created April 17, 2026, 21:33 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2020-02-06 00:00:00
open_canada_keywords {"fr": ["avis de modification", "Liste des drogues sur ordonnance", "LPD", "usage humain et vétérinaire", "gemtuzumab ozogamacin", "gilteritinib", "icosapent éthyl", "tafamidis", "trifarotine et upadacitinib."], "en": ["notice of amendment", "Prescription Drug List", "PDL", "human-and-veterinary use", "gemtuzumab ozogamacin", "gilteritinib", "icosapent ethyl", "tafamidis", "trifarotine and upadacitinib."]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Avis : Liste des drogues sur ordonnance (LDO) : additions multiples (2020-02-13)
update_frequency as_needed